ChemWerth Owned API Manufacturer Passes FDA Inspection

Share Article

ChemWerth-Sichuan Credit Pharmaceutical Joint Venture receives no Form 483s

News Image
We’re proud that our Credit-ChemWerth facility continues to be a model for meeting FDA standards for quality and compliance

ChemWerth, Inc. reports that the Credit-ChemWerth facility, a factory it owns and operates in joint venture with the Sichuan Credit Pharmaceutical Co., Ltd., in Luzhou City, Sichuan Province, China, has passed an US Food and Drug Administration (FDA) inspection with no Form 483 being issued.

Established in July 2007, Credit-ChemWerth develops and manufactures generic Active Pharmaceutical Ingredients for sale to regulated markets worldwide. ChemWerth tributes its proprietary “Six System + 1” regulatory and compliance program for its continued regulatory and compliance success.

Peter Werth, Founder and CEO commented, “Our regulatory and compliance expertise ensuring our manufacturing facilities are in a steady state of cGMP is a real value-added benefit for our factories and our customers. We’re proud that our Credit-ChemWerth facility continues to be a model for meeting FDA standards for quality and compliance."

About ChemWerth
Founded in 1982, ChemWerth is a full service generic API development and supply company. Chemwerth has expertise in manufacturing specialty API’s; developing non-infringement patent strategies; and, providing world class regulatory support. The company has manufacturing partners in China, India, Europe and the United States. For more information about the company please visit http://www.chemwerth.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jennifer Reale

Chris Hoag
@PrecisionBiosys
Follow >
Kenyon Hoag Associates
Like >
Visit website